Immunocore Holdings plc
IMCRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeImmunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune. At a $1.78B market cap, Immunocore Holdings plc ranks as a small-cap company within healthcare. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Market Cap
$1.78B
Beta
0.73
P/E (TTM)
—
P/E (Fwd)
-55.94
EPS (TTM)
$-0.56
EPS (Fwd)
$-0.63
ROE
-7.1%
ROA
-0.9%
Cash
$844.9M
Total Debt
$435.7M
Free CF
$58.6M
52W Change
-3.7%
Annual Financials
Cash vs Debt
Immunocore Holdings plc holds $844.9M in cash against $435.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $58.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -7.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $174.4M (2022) to $400.0M (2025), reflecting a 129% increase over the period.
As with any equity investment, IMCR carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Immunocore Holdings plc's trajectory.